Fail Safe Cell Therapy


Therapeutic properties of mesenchymal stem cells for autism spectrum disorders.

Benjamin Gesundheit, Paul Ashwood, Armand Keating, David Naor, Michal Melamed, Joshua P Rosenzweig
Med Hypotheses 2015 Mar 30;84(3):169-77. Epub 2014 Dec 30.

Recent studies of autism spectrum disorders (ASD) highlight hyperactivity of the immune system, irregular neuronal growth and increased size and number of microglia. Though the small sample size in many of these studies limits extrapolation to all individuals with ASD, there is mounting evidence of both immune and nervous system related pathogenesis in at least a subset of patients with ASD. Given the disturbing rise in incidence rates for ASD, and the fact that no pharmacological therapy for ASD has been approved by the Food and Drug Administration (FDA), there is an urgent need for new therapeutic options. Research in the therapeutic effects of mesenchymal stem cells (MSC) for other immunological and neurological conditions has shown promising results in preclinical and even clinical studies. MSC have demonstrated the ability to suppress the immune system and to promote neurogenesis with a promising safety profile…..


Sorry, comments are closed for this post.